Barclays PLC Buys 86,677 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Barclays PLC raised its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 128.2% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 154,297 shares of the biopharmaceutical company’s stock after acquiring an additional 86,677 shares during the period. Barclays PLC’s holdings in Vanda Pharmaceuticals were worth $722,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in VNDA. Meeder Asset Management Inc. bought a new stake in shares of Vanda Pharmaceuticals during the second quarter valued at approximately $39,000. ORG Wealth Partners LLC purchased a new position in Vanda Pharmaceuticals during the third quarter valued at $40,000. China Universal Asset Management Co. Ltd. lifted its position in Vanda Pharmaceuticals by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 4,374 shares during the period. XTX Topco Ltd bought a new stake in shares of Vanda Pharmaceuticals during the 2nd quarter valued at $75,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter worth about $84,000. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on VNDA shares. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Vanda Pharmaceuticals in a research report on Monday, December 23rd. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a report on Friday, December 27th. They set a “hold” rating for the company.

Insider Activity at Vanda Pharmaceuticals

In related news, Director Stephen Ray Mitchell sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total value of $25,850.00. Following the completion of the transaction, the director now directly owns 44,857 shares in the company, valued at $231,910.69. The trade was a 10.03 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 8.90% of the stock is currently owned by insiders.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ:VNDA opened at $4.79 on Wednesday. The business has a fifty day moving average price of $4.86 and a 200-day moving average price of $5.15. The company has a market capitalization of $279.30 million, a PE ratio of -17.11 and a beta of 0.76. Vanda Pharmaceuticals Inc. has a 1-year low of $3.46 and a 1-year high of $6.75.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.